LYEL — Lyell Immunopharma
Median target
$34
calls from the last 12 months
Implied return
+215.7%
median target vs. price
Coverage
3 analysts · 3 calls
updated in the last 12 months
Consensus
2/0/1+1 net
Buy / Hold / Sell
Which analysts are behind LYEL's consensus?
See every current rating, price target and the analysts' track records for Lyell Immunopharma — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 3 analysts with calls on LYEL updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
LYEL elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-10-12 | Insiders | Aguirre Jarrad MattieuChief Medical Officer | Insider sale | 422 sh @ $8.63 | $4K |
| 2026-09-10 | Insiders | Shook DavidOfficer | Insider sale | 500 sh @ $12.70 | $6K |
More: insider activity · executive branch · trending